- Home
- NECB vs ATAI Comparison
NECB vs ATAI Comparison
Compare NECB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- ATAI
- Stock Information
- Founded
- NECB 1934
- ATAI 2018
- Country
- NECB United States
- ATAI Germany
- Employees
- NECB N/A
- ATAI N/A
- Industry
- NECB Savings Institutions
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- NECB Finance
- ATAI Health Care
- Exchange
- NECB Nasdaq
- ATAI Nasdaq
- Market Cap
- NECB 263.6M
- ATAI 282.6M
- IPO Year
- NECB N/A
- ATAI 2021
- Fundamental
- Price
- NECB $23.65
- ATAI $1.41
- Analyst Decision
- NECB
- ATAI Strong Buy
- Analyst Count
- NECB 0
- ATAI 3
- Target Price
- NECB N/A
- ATAI $10.50
- AVG Volume (30 Days)
- NECB 38.3K
- ATAI 1.4M
- Earning Date
- NECB 04-21-2025
- ATAI 05-19-2025
- Dividend Yield
- NECB 3.15%
- ATAI N/A
- EPS Growth
- NECB 0.72
- ATAI N/A
- EPS
- NECB 3.44
- ATAI N/A
- Revenue
- NECB $104,392,000.00
- ATAI $308,000.00
- Revenue This Year
- NECB $2.80
- ATAI $65.58
- Revenue Next Year
- NECB $8.34
- ATAI N/A
- P/E Ratio
- NECB $6.70
- ATAI N/A
- Revenue Growth
- NECB 2.77
- ATAI N/A
- 52 Week Low
- NECB $16.51
- ATAI $1.03
- 52 Week High
- NECB $31.72
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- NECB 60.97
- ATAI 44.57
- Support Level
- NECB $22.85
- ATAI $1.36
- Resistance Level
- NECB $23.95
- ATAI $1.54
- Average True Range (ATR)
- NECB 0.79
- ATAI 0.09
- MACD
- NECB 0.17
- ATAI -0.00
- Stochastic Oscillator
- NECB 90.68
- ATAI 0.00
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.